Mylan Fact Sheet · Acquired Abbott’s non-U.S. developed markets specialty and branded generics...
2
Mylan is one of the world’s leading global pharmaceutical companies. Our medicines include generic, brand name and over-the-counter products in a variety of dosage forms and therapeutic categories, such as difficult-to-manufacture injectables, transdermal patches, topicals and HIV/AIDS antiretroviral (ARV) therapies. The company has innovative research and development capabilities and is one of the world’s largest active pharmaceutical ingredient (API) manufacturers. Mylan applies one global quality standard to all of our medications regardless of where they are produced. Our Mission At Mylan, we are committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we: • Innovate to satisfy unmet needs • Make reliability and service excellence a habit • Do what’s right, not what’s easy • Impact the future through passionate global leadership Creating better health for a better world. That’s what inspires Mylan’s mission of providing quality healthcare to the world’s 7 billion people, one person at a time. Global workforce: more than 40,000 Products: a global market portfolio of more than 2,700 separate products Product submissions: more than 3,400 new product submissions pending regulatory approval around the world Global presence: sell products in more than 165 countries and territories U.S. presence: one out of every 13 prescriptions dispensed in the U.S. – brand name or generic – is a Mylan product Manufacturing presence: operate more than 50 facilities around the globe R&D capabilities: include an extensive range of dosage forms and delivery systems, including oral solid doses, transdermal patches, injectables, respiratory inhalants, dermatologics, topicals, soft gel capsules, nasal sprays, solutions, suspensions, ophthalmics, ARVs and APIs ARV access: approximately 50% of people living with HIV/AIDS worldwide who are receiving treatment depend on a Mylan product Notable: member of S&P 500 *Not inclusive of Renaissance/Meda 2015 Revenue: $9.45 billion* Ticker: NASDAQ, TASE: MYL Fast Facts Mylan Fact Sheet
Transcript of Mylan Fact Sheet · Acquired Abbott’s non-U.S. developed markets specialty and branded generics...
Mylan is one of the world’s leading global pharmaceutical companies. Our medicines include generic, brand name and over-the-counter products in a variety of dosage forms and therapeutic categories, such as difficult-to-manufacture injectables, transdermal patches, topicals and HIV/AIDS antiretroviral (ARV) therapies. The company has innovative research and development capabilities and is one of the world’s largest active pharmaceutical ingredient (API) manufacturers. Mylan applies one global quality standard to all of our medications regardless of where they are produced.
Our MissionAt Mylan, we are committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we:
• Innovate to satisfy unmet needs
• Make reliability and service excellence a habit
• Do what’s right, not what’s easy
• Impact the future through passionate global leadership
Creating better health for a better world. That’s what inspires Mylan’s mission of providing quality healthcare to the world’s 7 billion people, one person at a time.
Global workforce: more than 40,000
Products: a global market portfolio of more than 2,700 separate products
Product submissions: more than 3,400 new product submissions pending regulatory approval around the world
Global presence: sell products in more than 165 countries and territories
U.S. presence: one out of every 13 prescriptions dispensed in the U.S. – brand name or generic – is a Mylan product
Manufacturing presence: operate more than 50 facilities around the globe
R&D capabilities: include an extensive range of dosage forms and delivery systems, including oral solid doses, transdermal patches, injectables, respiratory inhalants, dermatologics, topicals, soft gel capsules, nasal sprays, solutions, suspensions, ophthalmics, ARVs and APIs
ARV access: approximately 50% of people living with HIV/AIDS worldwide who are receiving treatment depend on a Mylan product
Notable: member of S&P 500
*Not inclusive of Renaissance/Meda
2015 Revenue: $9.45 billion* Ticker: NASDAQ, TASE: MYL
Fast
Fac
tsMylan Fact Sheet
Stay Connected
1961Founded by Milan “Mike” Puskar and Don Panoz in White Sulphur Springs,
West Virginia, U.S.
1973Became a publicly traded company
1984Received our first branded product approval
2002Generated more than $1 billion
in revenue for the first time
2007Went global with the acquisitions
of Matrix and Merck Generics
2012Helped champion the U.S. Food and Drug Administration Safety and Innovation Act
2013Acquired Agila Specialties and
became a global injectables leader
INNOVATION | INTEGRITY | RELIABILITY | SERVICE | TEAMWORK OUR VALUES
Our Evolution
Media Relations: +1.724.514.1968 [email protected]
Investor Relations: +1.724.514.1813 [email protected]
@MylanNews @MylanCareersMylan.com
2015Acquired Abbott’s non-U.S. developed markets
specialty and branded generics businessAcquired certain businesses from Famy Care
to become a global women’s healthcare leader
Leadership
Tony Mauro Chief Commercial Officer
Robert J. Coury Chairman
Powerful Global Commercial Presence*
U.S. One in 13 prescriptions in the U.S., brand name or generic, is filled with a Mylan product
India Mylan represents 20% of the Hepatitis C market share in India
Canada Mylan products are sold in eight out of 10 pharmacies in Canada
Europe Mylan holds leadership positions in several key European markets, including France, Italy, the Netherlands, Portugal and the U.K.
Japan Mylan has been the fastest grower in the Japan generics market for the last three years†
Australia Mylan is the No. 1 supplier by volume to Australia’s national pharmaceuticals program
NORTH AMERICA n Caguas, Puerto Rico l Decatur, Illinois D n Morgantown, West Virginia n Rockford, Illinois D l Saint-Hubert, Quebec D l San Antonio, Texas (3) D l St. Albans, Vermont l Sugar Land, Texas
n Oral Solid Doses: 23 l Complex Products: 9 s Injectables: 9 u Active Pharmaceutical Ingredients: 9 D Research and Development: 14
EUROPE D Cambridge, U.K. n Châtillon, France n Cologne, Germany n Confienza, Italy D n l Dublin, Ireland (2) D s Galway, Ireland n Komarom, Hungary l Merignac, France n Meyzieu, France D Monza, Italy D Radebeul, Germany D Sandwich, U.K. n Troisdorf, Germany s Warsaw, Poland
INDIA D n Ahmedabad n Aurangabad D s Bangalore (5) n Daman s Hosur D u Hyderabad (4) n Indore n Jadcherla n Jaggaiahpet u Mumbai n Nashik n Sarigam (2) s u Vizag (4)
JAPAN
n Katsuyama D n Kawagoe
AUSTRALIA
n Carole Park, Queensland
* Not inclusive of Renaissance/Meda † Excluding authorized generics
Heather Bresch Chief Executive Officer
Rajiv Malik President
Ken Parks Chief Financial Officer
2016Acquired topicals-focused specialty and generics business from RenaissanceAcquired Meda, a leading international
specialty pharmaceutical company
©2016 Mylan N.V. All rights reserved. (November 2016) Better Health for a Better World® and the Mylan logo are registered trademarks of Mylan Inc.NON-2016-0806
